This content is machine translated Myocardial infarction Survived a heart attack – and now? Post-infarct management up-to date After an acute myocardial infarction, postinfarction management is the focus of treatment. To prevent another coronary event, it is essential to identify and treat appropriate risk factors. Non-drug interventions have…
View Post 5 min This content is machine translated Chronic lymphocytic leukemia BTK inhibitors and other hopefuls The therapy of chronic lymphocytic leukemia (CLL) is currently undergoing rapid change. Increasingly, chemoimmunotherapy, which has been commonly used in the past, is being replaced by more targeted treatments. In…
View Post 3 min This content is machine translated Type 2 diabetes: insulin therapy - quo vadis? Basic insulin with once-weekly injection convinces An ultra-long-acting insulin analogue that only needs to be injected once a week is currently in development. The results of the clinical studies to date are promising. Insulin Icodec has…
View Post 6 min This content is machine translated Inflammatory dermatoses Acne and rosacea – current trends at a glance As with other skin diseases, research into the role of the microbiome and immunological factors is a current focus of research efforts in acne and rosacea. Since both are multifactorial…
View Post 5 min This content is machine translated Pemphigus diseases How this autoimmune dermatosis can be managed nowadays Blistering autoimmune dermatoses of the skin are among the rare diseases and are often fatal if left untreated. Intensive therapy can significantly improve the prognosis and quality of life of…
View Post 15 min This content is machine translated Parkinson's disease Place of COMT inhibitors in Parkinson’s disease therapy. Over time, fluctuations in efficacy may occur in Parkinson’s therapy with L-dopa. Then, the treatment of L-dopa induced dyskinesias and motor fluctuations represents the most important task in clinical practice.… CME-Test
View Post 2 min This content is machine translated Non-small cell lung cancer with EGRF mutation. New approval for osimertinib for adjuvant therapy Following convincing results from the Phase III ADAURA study, the indication for osimertinib was expanded in Switzerland. Thus, the drug may now also be used for adjuvant therapy in early-stage…
View Post 4 min This content is machine translated Skin cancer: epidemiological development Marked increase in incidence predicted As shown by large skin cancer registries and population-based studies, there is a continuing trend in Europe and worldwide towards an increase in new cases of melanocytic and non-melanocytic tumors.…
View Post 3 min This content is machine translated Mild Cognitive Impairment Significant cognition improvement through BrainXpert Energy Complex Patients with Mild Cognitive Impairment (MCI) benefit from taking BrainXpert Energy Complex twice daily. A six-month study proved that the special ketonic drink is an effective alternative source of energy…
View Post 3 min This content is machine translated Advanced pancreatic cancer First-line therapies in the Real Life Check Currently, gemcitabine plus Nab-paclitaxel and FOLFIRINOX are considered standard first-line therapies for advanced pancreatic cancer. So far, there is no direct comparison of these options. An analysis of the German…
View Post 5 min This content is machine translated Type 2 diabetes GLP-1 receptor agonists reduce multiple cardiovascular risk factors In addition to improving glycemic control, GLP-1 receptor agonists have proven additional cardiovascular benefits. Large endpoint studies have demonstrated reductions in myocardial infarction and stroke rates and cardiovascular mortality. Another…
